Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Take a brief audio tour around Scrip's Five Must-Know Things, this time for the business week ended 23 October 2020. 

In this edition, we take a look at generic impact on one firm’s sales outlook, a major legal settlement in the US, a potential European product approval, corporate performance in India, and mixed results at two big multinationals.

 

These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn and also via any Alexa-enabled smart speaker or the Alexa app. Just say "Alexa - ask Informa Pharma Intelligence to find podcasts." 

Stories mentioned in this episode:

(Also see "Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds" - Scrip, 21 Oct, 2020.)

(Also see "Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company" - Scrip, 21 Oct, 2020.)

(Also see "Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval" - Scrip, 16 Oct, 2020.)

(Also see "India Q2 Preview: Glenmark, Cipla Emerge Stronger" - Scrip, 20 Oct, 2020.)

(Also see "Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results" - Scrip, 20 Oct, 2020.)

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel